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Background. We investigated whether CD4:CD8 ratio and CD8 count were prognostic for all-cause, AIDS, and non-AIDS 
mortality in virologically suppressed patients with high CD4 count.
Methods. We used data from 13 European and North American cohorts of human immunodeficiency virus–infected, antiretro-
viral therapy (ART)–naive adults who started ART during 1996–2010, who were followed from the date they had CD4 count ≥350 
cells/μL and were virologically suppressed (baseline). We used stratified Cox models to estimate unadjusted and adjusted (for sex, 
people who inject drugs, ART initiation year, and baseline age, CD4 count, AIDS, duration of ART) all-cause and cause-specific mor-
tality hazard ratios for tertiles of CD4:CD8 ratio (0–0.40, 0.41–0.64 [reference], >0.64) and CD8 count (0–760, 761–1138 [reference], 
>1138 cells/μL) and examined the shape of associations using cubic splines.
Results. During 276 526 person-years, 1834 of 49 865 patients died (249 AIDS-related; 1076 non-AIDS-defining; 509 unknown/
unclassifiable deaths). There was little evidence that CD4:CD8 ratio was prognostic for all-cause mortality after adjustment for other 
factors: the adjusted hazard ratio (aHR) for lower vs middle tertile was 1.11 (95% confidence interval [CI], 1.00–1.25). The associ-
ation of CD8 count with all-cause mortality was U-shaped: aHR for higher vs middle tertile was 1.13 (95% CI, 1.01–1.26). AIDS-
related mortality declined with increasing CD4:CD8 ratio and decreasing CD8 count. There was little evidence that CD4:CD8 ratio 
or CD8 count was prognostic for non-AIDS mortality.
Conclusions. In this large cohort collaboration, the magnitude of adjusted associations of CD4:CD8 ratio or CD8 count with 
mortality was too small for them to be useful as independent prognostic markers in virally suppressed patients on ART.
Keywords. CD8 count; CD4:CD8 ratio; mortality; HIV; antiretroviral therapy.
 
CD4+ T-lymphocyte (CD4) counts and human immunode-
ficiency virus type 1 (HIV-1) RNA measurements (viral load 
[VL]) are the most important prognostic markers for disease 
progression and recovery after starting combination antiretro-
viral therapy (ART) in people living with HIV (PLWH) [1–4]; 
most AIDS-related deaths occur in patients with CD4 count 
<350 cells/μL [5]. However, PLWH on ART with CD4 count 
>350 cells/μL and suppressed VL experience higher mortality 
than the general population, mainly due to non-AIDS causes 
[6, 7]. The CD4:CD8 ratio and CD8+ T-lymphocyte (CD8) 
counts have been suggested as prognostic markers for mortality, 
in addition to VL and CD4 count, in such patients [8–12]. The 
Insight Strategic Timing of Antiretroviral Treatment (START) 
study group showed that in PLWH diagnosed with a CD4 count 
>500 cells/μL, those with a VL >50 000 copies/mL or with a 
CD4:CD8 ratio <0.5 benefited the most from early treatment 
compared with deferring treatment to when CD4 count reached 
350 cells/μL [13]. Moreover, they suggested that the best surro-
gate markers for the effect of early treatment on clinical outcomes 
were controlling the VL and increasing the CD4:CD8 ratio.
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CD8 counts increase in response to acute infection, but also 
remain raised in chronic infections such as HIV. CD8 counts 
respond to ART more slowly than CD4 counts. In the general 
population, CD4:CD8 ratio declines with age and is associated 
with mortality [14]. The ratio is considered to be a marker of 
cumulative inflammation and immunological changes associ-
ated with aging [15]. Results of previous studies that examined 
associations of CD4:CD8 ratio or CD8 count with mortality in 
HIV-infected patients on ART were inconsistent [16–21].
We investigated whether the CD4:CD8 ratio or CD8 counts 
were independently associated with all-cause, AIDS, and 
non-AIDS mortality in patients treated with ART with sup-
pressed VL and CD4 count >350 cells/μL using data from the 
Antiretroviral Therapy Cohort Collaboration (ART-CC).
METHODS
Eligibility
We combined data from 13 European and North American 
cohorts (see Appendix) participating in ART-CC (www.art-co-
hort-collaboration.org) [22]. Participation of cohorts has been 
approved by their ethics committees or institutional review 
boards according to local regulations. Cohorts use standard-
ized methods of data collection, and schedule follow-up visits 
at least every 6 months.
Eligible patients were ART naive and aged ≥16 years when 
they started a combination ART regimen containing at least 3 
antiretroviral drugs between 1996 and 2010. Follow-up began 
on the date after starting ART (baseline) when the patient’s CD4 
count first exceeded ≥350 cells/μL, a CD8 count measurement 
was recorded, and VL was lower than the limit of detection of 
the assay or <200 copies/μL). In a sensitivity analysis, baseline 
was defined as the date of the second successive CD4 count 
≥350 cells/μL with viral suppression. Patients were considered 
lost to follow-up if there was a gap of >1 year between the date 
the patient was last known to be alive and the cohort-specific 
database close date and were censored 6 months after the date 
they were last known to be alive. Database close date varied 
among cohorts between 31 May 2012 and 31 July 2013.
Cause of Death Information
Information on mortality was obtained either through linkage 
with vital statistics agencies and hospitals or through physician 
report and active follow-up of patients. We adapted the Cause 
of Death (CoDe) project protocol (www.cphiv.dk/CoDe.aspx) 
[23] to classify causes of death. We used a computer algorithm 
developed by the Mortalité 2000–2005 Study Group [24] to clas-
sify deaths where International Classification of Diseases, Tenth 
Revision (ICD-10) codes were available, which were also coded 
by a clinician and compared. For deaths described by free text, 
2 clinicians independently classified each death. Disagreements 
between clinicians and/or computer-assigned codes were 
resolved via panel discussion, as described previously [25, 26]. 
If information from ICD-10 codes or free text was insufficient to 
determine the cause, deaths were labeled “unclassifiable” and in 
these analyses were combined with deaths with no information 
and labeled “unknown.” Deaths were coded as AIDS-related if 
there was an AIDS-defining condition(s) close to death and/or 
a low CD4 count (<100 cells/μL) prior to death and a diagnosis 
compatible with AIDS as cause of death. All other deaths (exclud-
ing “unknown” deaths which were not included in analyses of 
cause-specific mortality) were assumed to be non–AIDS related.
Statistical Methods
Covariates included in multivariable models were chosen a priori 
from literature [27]. We categorized age (16–29, 30–39, 40–49, 
50–59, 60–69, and ≥70 years), year of ART initiation (1996–1999, 
2000–2003, 2004–2007, and 2008–2010), and baseline CD4 count 
(350–499, 500–749, and ≥750 cells/μL). We analyzed CD4:CD8 
ratio and CD8 count both as continuous variables using spline 
transformations to capture nonlinear associations flexibly and in 
tertiles of their distribution at baseline, to compare the magni-
tude of associations in the same metric. The knots for the cubic 
splines were positioned by default using Harrell recommended 
percentiles [28] at 0.3, 0.53, and 1.02 for CD4:CD8 ratio and at 
510, 909, and 1528 cells/μL for CD8 count. The tertile groups 
were 0–0.40, 0.41–0.64, and >0.64 for CD4:CD8 ratio and 0–760, 
761–1138, and >1138 cells/μL for CD8.
We plotted smoothed (using a moving average over 3 years) 
mean CD4 count, CD4:CD8 ratio, and CD8 count by time since 
baseline. We used Cox models stratified by cohort to estimate 
unadjusted, adjusted (for sex, age, people who inject drugs trans-
mission group, calendar period of ART initiation, AIDS status, 
time from ART initiation to baseline) and additionally adjusted 
(for baseline CD4 count) mortality hazard ratios (HRs) for the 
lowest and highest tertiles compared to the middle (reference) 
tertile for baseline CD4:CD8 ratio and CD8 count. Separate mod-
els were estimated for all-cause, AIDS-related, and non-AIDS-re-
lated mortality. In the analysis of AIDS-related mortality, those 
experiencing non-AIDS-related death were censored at date of 
death (and vice versa). In a sensitivity analysis we modeled AIDS 
and non-AIDS mortality using competing risks regression.
We modeled and plotted adjusted HRs (compared to the 
median) across the range of CD4:CD8 ratios and CD8 counts 
using spline transformations of these variables. Spline plots 
were truncated at 0.1 and 1.25 for CD4:CD8 ratio (97.5% of 
sample) and 10 and 2000 cells/μL for CD8 count (95% of sam-
ple). We used 2 degrees of freedom likelihood ratio (LR) tests to 
assess the evidence that CD4:CD8 ratio and CD8 count (mod-
eled using splines and as tertiles) were prognostic.
RESULTS
Characteristics
Of 66 610 patients with both CD4 and CD8 counts recorded, 
49 865 (75%) reached a CD4 count ≥350 cells/μL with suppressed 
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VL and therefore were included in analyses. Of these, 1834 died 
during 276 526 person-years (6.7 deaths/1000 person-years). 
Two hundred forty-nine deaths (14%) were AIDS-related, 1076 
(59%) non-AIDS-related, and 509 (28%) classified as unknown. 
Duration of ART before reaching CD4 ≥350 cells/μL was longer 
in those who started ART with a lower CD4 count. However, 
nearly half of patients in our analysis had undetectable VL and 
reached CD4 ≥350 cells/μL within 6 months of ART initiation 
(Table 1). Patient demographics and clinical characteristics at 
baseline are shown in Table 1. The median age was 37 (inter-
quartile range [IQR], 31–45) years. The median baseline CD4 
count, CD8 count, and CD4:CD8 ratio were 446 (IQR, 386–
566) cells/μL, 930 (IQR, 679–1271) cells/μL, and 0.52 (IQR, 
0.37–0.74), respectively. Baseline CD4 count was less correlated 
with CD4:CD8 ratio (r = 0.075) than with CD8 count (r = 0.128) 
(difference in correlations P < .0001).
Trajectories of Biomarkers Over Time
Smoothed mean CD4 count, CD8 count, and CD4:CD8 ratio 
up to 10 years after baseline are shown in Figure 1. Mean CD4 
count increased steadily, from 507 to 678 cells/μL at 10 years. 
Mean CD8 count declined from 1040 at baseline to 942 cells/μL 
at 1 year, then plateaued at around 930 cells/μL. Mean CD4:CD8 
ratio increased sharply from 0.49 at baseline to 0.58 at 1 year, 
then less rapidly to 0.73 at 10 years.
All-Cause Mortality
Rates of all-cause mortality declined with increasing CD4:CD8 
ratio (Figure 2), but confidence intervals (CIs) were wide and 
there was little evidence (LR P = .17) that CD4:CD8 ratio was 
prognostic after adjusting for other variables. In contrast, CD8 
count showed a U-shaped association with all-cause mortality 
after adjusting for other variables (LR P  =  .007), with lowest 
mortality rates near the median value and highest rates for those 
with high CD8 counts (Figure 2). Before adjustment, lower ter-
tile of baseline CD4:CD8 ratio (hazard ratio [HR], 1.20 [95% 
CI, 1.08–1.34]) and higher tertile of CD8 count (HR, 1.26 [95% 
CI, 1.13–1.41]) were each associated with higher all-cause mor-
tality compared with the middle (reference) tertile (Table 2), but 
associations were attenuated after adjustment to 1.11 (95% CI, 
1.00–1.25) and 1.13 (95% CI, 1.01–1.26), respectively. Neither 
tertiles of CD4:CD8 ratio nor of CD8 count were prognostic for 
all-cause mortality (LR P = .16 and P = .11, respectively).
AIDS-Related Mortality
AIDS-related mortality declined with increasing CD4:CD8 
ratio (LR P =  .005) and decreasing CD8 count (LR P =  .009) 
(Figure 3). The adjusted hazard ratio (aHR) for AIDS-related 
Table  1. Characteristics (Within 3 Months) of Patients at Start of 
Follow-up (Baseline) (N=49 865)
Variable Patients, No. (%)
Female sex 13 724 (28)
PWID transmission 3638 (7)
AIDS 9283 (19)
Age, y
 16–29 7425 (15)
 30–39 18 487 (37)
 40–49 15 204 (30)
 50–59 6296 (13)
 60–69 2060 (4)
 ≥70 393 (0.8)
Years from ART start to reaching CD4 count ≥350 cells/μL 
(rounded to nearest year)a
 0 23 693 (48)
 1 11 440 (23)
 2 4939 (10)
 3 2953 (6)
 4 1893 (4)
 ≥5 4947 (10)
Calendar period of ART initiation
 1996–1999 11 739 (24)
 2000–2003 11 763 (24)
 2004–2007 12 369 (25)
 2008–2012 13 994 (28)
CD4 count, cells/μL
 350–499 31 779 (64)
 500–749 13 367 (27)
 ≥750 4719 (9)
CD4:CD8 ratio
 0–0.40 16 276 (33)
 0.41–0.64 17 011 (34)
 >0.64 16 578 (33)
CD8 count, cells/μL
 0–760 16 671 (33)
 761–1138 16 583 (33)
 >1138 16 611 (33)
CD8 and CD4:CD8 have been split into tertiles calculated when the patients reach baseline. 
Baseline was defined as date of reaching a CD4 count ≥350 cells/μL with an undetectable 
viral load (lower than lower limit of viral assay or <200 copies/mL).
Abbreviations: ART, antiretroviral therapy; PWID, people who inject drugs.
aYear 0 contains those who reached a CD4 count ≥350 cells/μL ≤6 months after ART start.
Figure 1. Smoothed mean CD4 count, CD8 count, and CD4:CD8 ratio, by years 
after baseline (reaching a CD4 count ≥350 cells/μL and viral suppression).
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mortality for the lowest (vs middle) tertile of CD4:CD8 ratio 
was 1.28 (95% CI, .95–1.73) and for the highest (vs middle) ter-
tile of CD8 was 1.36 (95% CI, 1.01–1.84) (Table 2). Tertiles of 
both CD4:CD8 ratio and CD8 count were prognostic for AIDS-
related deaths (LR P = .016 and P = .0037, respectively).
Non-AIDS-Related Mortality
When CD4:CD8 ratio was modeled as a continuous variable, 
there was no evidence (LR P =  .79) that it was prognostic for 
non-AIDS-related mortality (Figure  3). However, there was 
weak evidence (LR P  =  .1) that mortality was higher in the 
lower and upper tertiles compared with the middle tertile of 
CD4:CD8 ratio (aHR, 1.10 [95% CI, .95–1.28] and 1.19 [95% 
CI, 1.01–1.39], respectively). CD8 count had a u-shaped asso-
ciation with non-AIDS mortality (Figure 3), but there was little 
evidence that it was prognostic after adjusting for other varia-
bles (LR P = .14 for continuous and P = .38 for tertiles).
In sensitivity analyses (1) using competing risk regression 
and (2) starting follow-up from second CD4 count >350 cells/
μL (Supplementary Table 1), estimates were similar to those in 
the main analysis.
DISCUSSION
Based on a large dataset combined from European and North 
American clinical cohorts, we compared the utility of CD4:CD8 
ratio and CD8 count as prognostic markers for mortality in 
PLWH on ART with suppressed VL and CD4 counts >350 
cells/μL. Although mean CD8 counts decreased immediately 
after baseline, they plateaued at a level considered higher than 
normal in the general population. Mean CD4 count continued 
to increase over 10  years of follow-up. Mean CD4:CD8 ratio 
Table 2. Mortality Hazard Ratios for All-Cause, AIDS-Related, and Non-AIDS-Related Deaths Across Tertiles of CD4:CD8 Ratio and CD8 Count (N = 49 865) 
Mortality
CD4:CD8 Ratio
LR P 
Value
CD8 Count, Cells/μL
LR P 
Value0–0.40 0.41–0.64 >0.64 0–760 761–1138 >1138
All-cause mortality
 Unadjusted 1.20 (1.08–1.34) 1 1.05 (.93–1.18) .003 1.04 (.92–1.17) 1 1.26 (1.13–1.41) <.001
 Adjusted, no CD4a 1.10 (.98–1.23) 1 1.12 (1.00–1.27) .11 1.04 (.92–1.17) 1 1.14 (1.02–1.27) .06
 Fully adjustedb 1.11 (1.00–1.25) 1 1.07 (.95–1.21) .16 1.05 (.93–1.18) 1 1.13 (1.01–1.26) .11
AIDS mortality
 Unadjusted 1.39 (1.04–1.86) 1 0.82 (.59–1.15) .003 0.94 (.66–1.32) 1 1.55 (1.15–2.09) .001
 Adjusted, no CD4a 1.23 (.92–1.65) 1 0.87 (.62–1.22) .095 0.93 (.66–1.32) 1 1.38 (1.02–1.86) .024
 Fully adjustedb 1.28 (.95–1.73) 1 0.77 (.54–1.10) .016 0.94 (.67–1.33) 1 1.36 (1.01–1.84) .037
Non-AIDS mortality
 Unadjusted 1.20 (1.04–1.39) 1 1.15 (.99–1.34) .039 1.08 (.92–1.25) 1 1.23 (1.06–1.42) .016
 Adjusted, no CD4a 1.10 (.95–1.27) 1 1.24 (1.06–1.44) .026 1.08 (.93–1.26) 1 1.11 (.96–1.29) .35
 Fully adjustedb 1.10 (.95–1.28) 1 1.19 (1.01–1.39) .097 1.09 (.93–1.27) 1 1.10 (.95–1.27) .38
Data are presented as hazard ratio (95% confidence interval) unless otherwise indicated. Deaths: all-cause = 1834; AIDS-related = 249; non-AIDS-related = 1076. Likelihood ratio P value is 
a test with 2 degrees of freedom for models containing CD4:CD8 ratio or CD8 ratio term against models without these terms.
Abbreviation: LR, likelihood ratio.
aThe same as the fully adjusted analysis but without adjustment for CD4.
bAdjusted for sex, AIDS status, CD4 count, age, and viral load at baseline; time from antiretroviral therapy (ART) initiation to baseline; calendar year of ART initiation; injection drug use 
transmission; and stratified by cohort.
Figure  2. Adjusted hazard ratios (HRs) for all-cause mortality with median as 
comparator for CD4:CD8 ratio (upper panel) and CD8 count (lower panel), based on 
cubic spline models and adjusted for other prognostic variables. Gray-shaded area 
indicates the 95% confidence interval and the vertical lines indicate the median and 
interquartile range. Abbreviation: LR, likelihood ratio.
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also increased during follow-up, mostly due to increases in 
CD4 rather than decreases in CD8 counts, but remained short 
of the mean in the general population: 1.8 [29]. Associations 
of CD4:CD8 ratio and CD8 count with all-cause mortality 
were attenuated after adjustment for other prognostic factors 
at baseline; there was little evidence that CD4:CD8 ratio was 
prognostic independent of CD4 count. The association of CD8 
count with all-cause mortality appeared U-shaped, with higher 
mortality for those with higher and lower values compared 
with those with values near the median. AIDS-related mortality 
declined with increasing CD4:CD8 ratio and decreasing CD8 
count. There was little evidence that CD4:CD8 ratio or CD8 
count was independently prognostic for non-AIDS mortality.
Immune Dysregulation and Inflammatory Processes
Viral infections such as HIV cause a high turnover of T cells and 
an accumulation of CD8 [15]. Elevated CD8 count is a marker 
of immune dysregulation and ongoing inflammatory processes, 
which may lead to increased non-AIDS-related morbidity and 
mortality in those treated long term for HIV infection [20]. 
In the general population, CD4:CD8 ratios decrease with age; 
many T-cell abnormalities related to aging have been observed 
at younger ages in HIV-infected individuals [15]. Inflammation 
is associated with untreated HIV infection, but ART has differ-
ential effects on markers of inflammation with some declining 
more than others: Interleukin 6, C-reactive protein, cystatin C, 
and D-dimer remain elevated with successful ART [15, 30, 31].
All-Cause Mortality
Studies that followed patients for mortality from ART start have 
found that the dominant prognostic marker is CD4 count and 
the majority of deaths are AIDS related [9]. If a patient’s CD4 
count is very low at ART start, then their CD8 count will also be 
low. This correlation between CD4 and CD8 count at ART start 
in immunosuppressed patients implies that the ratio is unlikely 
to be a useful predictor of mortality in the first year of ART [32]. 
However, in the START trial, which included only patients who 
were not immunosuppressed, low CD4:CD8 ratio was associ-
ated with the primary endpoint, which included serious AIDS 
and non-AIDS morbidity as well as all-cause mortality [13].
Figure 3. Plots of adjusted hazard ratio (HR) of AIDS-related (left panels) and non-AIDS-related (right panels) mortality with median as comparator for CD4:CD8 ratio 
(upper panels) and CD8 count (lower panels) with 95% confidence intervals. Modeled using cubic splines. The vertical lines indicate the median and interquartile range. 
Abbreviation: LR, likelihood ratio test.
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A study from the Danish HIV cohort illustrates the difficulty 
of interpreting CD8 count as a prognostic marker. Mortality was 
predicted by low CD8 count (<500 cells/μL) at ART start, but by 
high CD8 count 1 year afterward (>2000 cells/μL) and 10 years 
afterward (>1500 cells/μL) [20]. The latter 2 results are in con-
cordance with our findings, which applied only to those with 
a relatively high CD4 count. Two other studies that included 
patients with no CD4 count restriction from ART start found 
that low CD8 count predicted AIDS events or all-cause mor-
tality [3, 19]. In contrast, a large French study did not find that 
CD4:CD8 ratio or CD8 count added prognostic value for all-
cause mortality independent of CD4 in patients with CD4 count 
>200 cells/μL [21], similar to our findings. These studies used a 
range of cutoff values for CD4:CD8 ratio or CD8 count, and did 
not always control for CD4 count, making comparisons difficult.
AIDS-Related Mortality
In contrast to our study, which found that high CD8 count 
was associated with AIDS-related mortality, the Danish study 
found that low CD8 count (<500 cells/μL) 1 year after ART start 
was associated with an increased risk [20]. Again the different 
results could be due to the difference in patient populations and 
sample size. Interestingly, CD8 count <400 cells/μL specifically 
predicted occurrence of pneumonia and death in a study based 
in the United States [33]. In agreement with our finding of low 
CD4:CD8 ratio associated with AIDS-related mortality, albeit 
with wide CIs due to few deaths, an Italian study also found 
an association of low CD4:CD8 ratio with higher risk of AIDS 
events and AIDS-related deaths among virally suppressed 
patients [18].
Non-AIDS-Related Mortality
The CD4 count measured at ART start loses its predictive value 
as duration of ART increases, whereas CD4:CD8 ratio has, at 
least in some studies, been found to predict non-AIDS morbid-
ity and mortality after long-term ART [34]. A small case-con-
trol study reported an association between low CD4:CD8 ratio 
and serious non-AIDS-related events [16, 17], but in a study 
that included data from 4 cohorts and 3 trials, this result failed 
to replicate in those with high CD4 count [16]. A larger Italian 
study of patients with suppressed VLs found an elevated risk 
of non-AIDS mortality in those with CD4:CD8 <0.3 compared 
with between 0.3 and 0.8 [18], whereas we found little evidence 
that CD4:CD8 ratio or CD8 count was independently prognos-
tic for non-AIDS mortality. Studies have also found associations 
between low CD4:CD8 ratio and coronary artery disease, but 
were underpowered to consider mortality [35].
Strengths and Weaknesses
Our study is observational and therefore there may be unmeas-
ured confounding, by factors such as, for example, smoking. 
Although there is uncertainty about the outcome of patients lost 
to follow-up, we would have known if they had died, as most 
cohorts link to death registries. Strengths of this study include 
prospective study design and the large sample size and num-
bers of deaths which were coded by a standard procedure. Our 
results are likely generalizable across high-resource settings as 
contributing cohorts came from a wide range of countries and 
the sample size was much larger than any previous studies of 
CD8 as a prognostic marker in the treated HIV-infected popu-
lation [34]. Estimating associations of CD4:CD8 ratio and CD8 
count using tertiles allowed us to compare HRs based on the 
same metric and, together with models based on cubic splines, 
allowed us to examine the shape of associations across the range 
of each measure.
Implications
Our data show that CD8 count recovers less well than CD4 
count and remains high for a lengthy period, as has been 
observed in other studies [20], which may indicate ongoing 
immune dysregulation. This implies a need for increased mon-
itoring and early start of treatment before the CD8 count is ele-
vated to levels it will not recover from. The consequences of 
this may be seen in a longer period of follow-up than we have 
been able to study here as our results show little evidence that 
CD4:CD8 is associated with all-cause mortality in a HIV pop-
ulation with high CD4 counts and suppressed VLs. There is 
slightly more evidence of an association with CD8 count and 
all-cause mortality in this population but the pattern was not 
strong despite the large size of our dataset, indicating little use-
fulness as a prognostic factor for all-cause mortality. The same 
could be said of the association of both CD4:CD8 ratio and 
CD8 count with non-AIDS mortality, although it is possible 
that associations may only be with specific causes of morbidity 
and death that we were unable to look at here. Our finding that 
both low CD4:CD8 ratio and high CD8 count were associated 
with AIDS mortality in this population with high CD4 counts 
and suppressed VLs implies that both CD4:CD8 ratio and CD8 
count could account for some excess AIDS mortality in a HIV 
population that was otherwise healthy.
CONCLUSIONS
Our study of patients treated with ART who are virally sup-
pressed and have CD4 count >350 cells/μL, which is the larg-
est to date investigating the associations of CD4:CD8 ratio and 
CD8 count with cause-specific mortality, does not lend strong 
support to using either measurement as a prognostic marker 
for non-AIDS related mortality. However, the failure of many 
patients in this long-term treated HIV-infected population to 
reach the levels of CD4:CD8 ratio or CD8 count considered 
to be normal in the general population may indicate ongoing 
immune dysregulation. This may have longer-term conse-
quences than we have been able to study here, or associations 
may be only with specific causes of death. Therefore, these 
markers might contribute to the immunological evaluation of 
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patients in long-term follow-up. Nevertheless, our results show-
ing poor CD4:CD8 ratio recovery support treatment earlier in 
the course of HIV infection to better preserve immune function 
in PLWH as is now recommended by treatment guidelines.
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